ARS Pharmaceuticals, Inc. has announced the filing for approval of neffy® (epinephrine nasal spray) 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy®. This follows neffy's ...

ADALAT® XL® (nifedipine extended-release tablets) first received market authorization in Canada in 1995 and is indicated for the management of chronic stable angina and the management of mild to ...

TORONTO--(BUSINESS WIRE)--Today, Juno Pharmaceuticals Canada (“Juno”), a leader in the commercialization of specialty pharmaceuticals, announced the acquisition of Omega Laboratories (“Omega”), one of ...

The Canadian pharmaceutical landscape has been undergoing significant transformations, driven by technological advancements, policy shifts, and evolving healthcare needs. At the forefront of this ...

PARSIPPANY, N.J. & OAKVILLE, Ontario--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive ...

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions Under the terms ...

Otsuka Pharmaceutical Canada Inc. (OCPI) and Lundbeck Canada Inc. (Lundbeck) have secured coverage of ABILIFY ASIMTUFII® for over 90 per cent of Canadians covered by public drug plans and almost 60 ...

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Canada, Kye Pharmaceuticals, has announced that Health Canada has accepted the New Drug Submission, NDS, for AGAMREE, a novel ...

MISSISSAUGA, ON, Jan. 13, 2026 /PRNewswire/ - Kye Pharmaceuticals ("Kye"), a Canadian specialty pharmaceutical company based in Mississauga, Ontario, today announced that it has entered into a ...

TORONTO--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI® (maralixibat) oral solution and ...

Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.

CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals (CPRX), Inc. , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing ...